# EDGAR Filing Document

**Accession Number:** 0002011674
**File Stem:** 0001213900-25-091940
**Filing Date:** 2025-9
**Character Count:** 4489
**Document Hash:** 1910edc5f10054086c088103456a4107
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-091940.hdr.sgml**: 20250926

**ACCESSION NUMBER**: 0001213900-25-091940

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250926

**FILED AS OF DATE**: 20250926

**DATE AS OF CHANGE**: 20250926

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** YD Bio Ltd
- **CENTRAL INDEX KEY:** 0002011674
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42810
- **FILM NUMBER:** 251345504

**BUSINESS ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039
- **BUSINESS PHONE:** 619-500-7747

**MAIL ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** True Velocity, Inc./DE
- **DATE OF NAME CHANGE:** 20240209

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16 UNDER<br> THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2025**

**Commission File Number: 001-42810**

**YD Bio Limited**

**(Exact name of registrant as specified in its charter)** 

**12F., No. 3, Xingnan St., Nangang Dist., Taipei City 115001, Taiwan**

**(Address of principal executive office)** 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**Departure of Chief Operating Officer**

On September 24, 2025, Ms. May Tsai, Chief Operating Officer of YD Bio Limited (the "Company"), tendered her resignation for personal health reasons, effective as of September 24, 2025. Ms. Tsai's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

The Company commenced a search for a new Chief Operating Officer. Following Ms. Tsai's resignation, the Company engaged Ms. Nina Wu as a strategic consultant. Ms. Wu will assist with investor communications and manage the Company's interaction with the capital markets. Ms. Wu previously worked with Taiwan Sotheby's International Realty under the Primasia Group from 2012 to 2022 and served as Investor Director at Trade & Investment Queensland's Taiwan Office, where she engaged leading institutions, multinational corporations, and government agencies in 2023.

**Registration of the Shares Underlying the Public Warrants and Exercisability of the Company's Public Warrants**

The Company has filed a registration statement on [Form F-1](https://www.sec.gov/Archives/edgar/data/2011674/000121390025090653/ea0257287-f1_ydbio.htm) (File No. 333-290471) (the "Registration Statement") dated September 23, 2025 to register the offer and sale of ordinary shares held by certain shareholders and the ordinary shares issuable upon exercise of private placement warrants. In light of the recent event, the Company plans to amend the Registration Statement to include the registration of the issuance of ordinary shares underlying the publicly traded warrants (the "Public Warrants") which trade on Nasdaq under the ticker, YDESW. The Public Warrants will not become exercisable until the Registration Statement is amended and declared effective by the U.S. Securities and Exchange Commission. If the Registration Statement covering the Ordinary Shares underlying the Public Warrants is not effective by the 60th business day following the closing of the business combination—or if at any time thereafter the registration statement is not maintained as effective and current—holders may exercise their Public Warrants on a cashless basis during such periods of ineffectiveness.

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **YD Bio Limited** | **YD Bio Limited** |
| By: | /s/ Ethan Shen |
| Name: | Ethan Shen |
| Title: | Chief Executive Officer and Chairman |

---

Date: September 26, 2025